Guangdong Lifestrong Pharmacy Co., Ltd. (SHE:301111)
China · Delayed Price · Currency is CNY 20.51
+0.03 (0.15%)
Feb 4, 2026, 3:14 PM CST
SHE:301111 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 273.86 | 274.19 | 292.15 | 283.29 | 349.44 | 339.46 |
Other Revenue | 4.45 | 4.45 | 0.25 | 0.05 | 0.35 | 1.5 |
| 278.31 | 278.64 | 292.4 | 283.34 | 349.79 | 340.96 | |
Revenue Growth (YoY) | -11.68% | -4.71% | 3.20% | -19.00% | 2.59% | 7.70% |
Cost of Revenue | 84.21 | 89 | 94.55 | 92.74 | 107.53 | 114.8 |
Gross Profit | 194.1 | 189.64 | 197.85 | 190.6 | 242.26 | 226.15 |
Selling, General & Admin | 208.91 | 188.54 | 164.31 | 155.88 | 165.38 | 145.83 |
Research & Development | 8.67 | 8.41 | 8.44 | 9.16 | 10.87 | 10.55 |
Other Operating Expenses | 4.71 | 3.03 | -0.62 | 1.72 | 4.71 | 4.44 |
Operating Expenses | 222.27 | 198.36 | 173.39 | 166.77 | 181.75 | 161.83 |
Operating Income | -28.17 | -8.71 | 24.46 | 23.83 | 60.51 | 64.33 |
Interest Expense | -4.38 | -2.46 | -0.37 | -0.03 | -0.06 | - |
Interest & Investment Income | 7.56 | 12.45 | 14.6 | 14.25 | 4.03 | 1.78 |
Currency Exchange Gain (Loss) | - | - | - | - | - | -0.01 |
Other Non Operating Income (Expenses) | -1.09 | -1.93 | -1.01 | -0.03 | -0.04 | -0.3 |
EBT Excluding Unusual Items | -26.08 | -0.66 | 37.68 | 38.03 | 64.44 | 65.8 |
Gain (Loss) on Sale of Investments | 0.57 | 1.67 | 2.78 | 2.93 | 1.55 | 0.29 |
Gain (Loss) on Sale of Assets | -1.79 | - | - | -0.33 | -0.01 | -0.25 |
Asset Writedown | -2.63 | -1.02 | -3.8 | -8.4 | -5.69 | - |
Other Unusual Items | 0.23 | -0.14 | 0.63 | 2.52 | 6.44 | 6.63 |
Pretax Income | -29.7 | -0.14 | 37.29 | 34.75 | 66.72 | 72.46 |
Income Tax Expense | -5.34 | -1.38 | 4.76 | 1.33 | 9.54 | 9.94 |
Earnings From Continuing Operations | -24.36 | 1.24 | 32.53 | 33.42 | 57.18 | 62.52 |
Minority Interest in Earnings | 6.29 | 2.92 | 0.97 | 0 | - | - |
Net Income | -18.07 | 4.16 | 33.5 | 33.42 | 57.18 | 62.52 |
Net Income to Common | -18.07 | 4.16 | 33.5 | 33.42 | 57.18 | 62.52 |
Net Income Growth | - | -87.58% | 0.25% | -41.56% | -8.54% | -6.17% |
Shares Outstanding (Basic) | 139 | 139 | 160 | 159 | 119 | 120 |
Shares Outstanding (Diluted) | 139 | 139 | 160 | 159 | 119 | 120 |
Shares Change (YoY) | -12.50% | -13.02% | 0.25% | 33.59% | -0.92% | 1.05% |
EPS (Basic) | -0.13 | 0.03 | 0.21 | 0.21 | 0.48 | 0.52 |
EPS (Diluted) | -0.13 | 0.03 | 0.21 | 0.21 | 0.48 | 0.52 |
EPS Growth | - | -85.71% | - | -56.25% | -7.69% | -7.14% |
Free Cash Flow | -2.84 | -34.69 | -51.41 | 64.34 | 68.54 | 44.8 |
Free Cash Flow Per Share | -0.02 | -0.25 | -0.32 | 0.40 | 0.57 | 0.37 |
Dividend Per Share | 0.050 | 0.050 | 0.100 | 0.100 | 0.160 | - |
Dividend Growth | -50.00% | -50.00% | - | -37.50% | - | - |
Gross Margin | 69.74% | 68.06% | 67.66% | 67.27% | 69.26% | 66.33% |
Operating Margin | -10.12% | -3.13% | 8.37% | 8.41% | 17.30% | 18.87% |
Profit Margin | -6.49% | 1.49% | 11.46% | 11.79% | 16.35% | 18.34% |
Free Cash Flow Margin | -1.02% | -12.45% | -17.58% | 22.71% | 19.59% | 13.14% |
EBITDA | -17.49 | 2 | 35.21 | 35.14 | 74.6 | 75.72 |
EBITDA Margin | -6.29% | 0.72% | 12.04% | 12.40% | 21.33% | 22.21% |
D&A For EBITDA | 10.68 | 10.71 | 10.75 | 11.31 | 14.1 | 11.39 |
EBIT | -28.17 | -8.71 | 24.46 | 23.83 | 60.51 | 64.33 |
EBIT Margin | -10.12% | -3.13% | 8.37% | 8.41% | 17.30% | 18.87% |
Effective Tax Rate | - | - | 12.76% | 3.83% | 14.30% | 13.72% |
Revenue as Reported | 278.31 | 278.64 | 292.4 | 283.34 | 349.79 | 340.96 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.